Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis

Arno Verleye, Veerle Wijtvliet, Steven Abrams, Rachel Hellemans, Rania Bougrea, Annick Massart, Lissa Pipeleers, Karl Martin Wissing, Kevin K Ariën, Benedicte Y De Winter, Pierre Van Damme, Daniel Abramowicz, Kristien J Ledeganck

Research output: Contribution to journalA1: Web of Science-article

Abstract

BACKGROUND: In the general population, the seroconversion rate after primary vaccination with two doses of an anti-SARS-CoV-2 mRNA vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared to BNT162b2 vaccination. Here, we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients.

METHODS: A systematic literature research was performed in Pubmed, Web of Science, and the Cochrane library and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated.

RESULTS: Eight studies that described the development of antibodies against receptor-binding domain (RBD) and/or spike protein were eligible for meta-analysis. Two of these studies also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 (44.3%; 95% confidence interval (CI): [34.1%-54.7%]) as compared to such patients vaccinated with two doses of mRNA-1273 (58.4%; 95% CI: [47.2%-69.2%]). The relative seroconversion rate amounted 0.795 (95% CI: [0.732-0.864]).

CONCLUSIONS: This systematic review and meta-analysis indicates that, in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared to BNT162b2.

Original languageEnglish
JournalNephrology, Dialysis, Transplantation
ISSN0931-0509
DOIs
Publication statusE-pub ahead of print - 2022

Cite this